Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiolabeled venglustat excretion and pharmacokinetics study in healthy males
NCT05238714Phase 1Completed
- Sponsor
- Sanofi
- Start
- May 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venglustat, sponsored by Sanofi. Primary endpoints: Percentage of radioactive dose excreted in urine and faeces at 43 days, Maximum concentration of plasma and blood radioactivity at 43 days and 4 more. Started May 2020; status: completed.
02
Drugs
venglustat
Beyond the preview
Go deeper on NCT05238714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238714.